ESR1 and breast cancer: In breast cancer, PKCθ may inhibit nuclear estrogen receptor, ERα, transcription through its activation of the Akt/FOXO3a pathway, resulting in increased activity of c-Rel and expression of target genes, including c-Myc [89].